Xenoestrogenic activity in blood of European and Inuit populations by Bonefeld-Jorgensen, Eva C et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Environmental Health: A Global 
Access Science Source
Open Access Research
Xenoestrogenic activity in blood of European and Inuit populations
Eva C Bonefeld-Jorgensen*1, Philip S Hjelmborg1, Thayaline S Reinert1, 
Birgitte S Andersen1, Vladimir Lesovoy2, Christian H Lindh3, Lars Hagmar3, 
Aleksander Giwercman4, Mogens Erlandsen5, Gian-Carlo Manicardi6, 
Marcello Spanò7, Gunnar Toft8 and Jens Peter Bonde8
Address: 1Unit of Cellular and Molecular Toxicology, Department of Environmental and Occupational Medicine, Institute of Public Health, Vennelyst 
Boulevard 6, Build. 1260, University of Aarhus, DK-8000 Aarhus, Denmark, 2Regional Clynical Center of Urology and Nephrology, Kharkiv, Ukraine, 
3Department of Occupational and Environmental Medicine, University Hospital, SE-22185 Lund, Sweden, 4Scanian Fertility Centre, Malmö 
University Hospital, SE-20502 Malmö, Sweden, 5Department of Biostatistics, Institute of Public Health, University of Aarhus, Vennelyst Boulevard 6, 
Build. 1260, DK-8000 Aarhus, Denmark, 6Laboratory of Genetics, Department of Agricultural Sciences, University of Modena and Reggio Emilia, Viale 
Kennedy 17, I-42100 Reggio Emilia, Italy, 7Section of Toxicology and Biomedical Sciences, BIOTEC-MED, ENEA Casaccia, Via Anguillarese 301, I-
00060 Rome, Italy and 8Department of Occupational Medicine, Aarhus University Hospital, Noerrebrogade 44, Build.2C, DK-8000 Aarhus, Denmark
Email: Eva C Bonefeld-Jorgensen* - ebj@mil.au.dk; Philip S Hjelmborg - phj@mil.au.dk; Thayaline S Reinert - line_job1@hotmail.com; 
Birgitte S Andersen - bsa@mil.au.dk; Vladimir Lesovoy - dimusic@ic.kharkov.ua; Christi a nHL i n d h-C h r i s t i a n . Lindh@med.lu.se; 
Lars Hagmar - lars.hagmar@ymed.lu.se; Aleksander Giwercman - aleksander.giwercman@kir.mas.lu.se; 
Mogens Erlandsen - mogens@biostat.au.dk; Gian-Carlo Manicardi - manicardi.giancarlo@unimo.it; 
Marcello Spanò - spanomtc@mail.casaccia.enea.it; Gunnar Toft - gutof@as.aaa.dk; Jens Peter Bonde - jpbon@as.aaa.dk
* Corresponding author    
Abstract
Background: Human exposure to persistent organic pollutants (POPs) is ubiquitous and found in all individuals. Studies have
documented endocrine disrupting effects and impact on reproduction. The aim of the present study was to compare the level
of xenoestrogenic activity in serum of groups with varying POP exposure, and to evaluate correlations to the POP biomarkers,
2,2',4,4',5,5'-hexachlorobiphenyl (CB-153) and 1,1-dichloro-2,2-bis (p-chlorophenyl)-ethylene (p,p'-DDE).
Methods: The study included 358 men: Greenlandic Inuit's, Swedish fishermen, and Warsaw (Poland) and Kharkiv (Ukraine)
inhabitants. Xenoestrogenicity of serum extracts alone (XER) and XER competitive (XERcomp) effect on 17β-estradiol induced
estrogen receptor (ER) transactivity were assessed in the hormone free, lipophilic serum fraction containing the POPs using the
MVLN human breast cancer cell line.
Results: No agonistic XER activity was exhibited for Inuit serum samples, while 12 – 24% of the European samples had
detectable agonistic XER activity. On the contrary, 71% of Inuit serum samples antagonized XERcomp compared to 7 – 30 % in
the other regions. XER and XERcomp were not or weakly correlated to the two POP markers. XER activity of Inuit samples
was negatively associated to levels of CB-153 and p,p'-DDE. For the Warsaw group a positive and negative correlation between
XER and p,p'-DDE and estradiol equivalence level and CB-153 levels was found.
Conclusion: No strong consistent association between xenoestrogenic net activity and the two POP markers was found. The
results showed that the selected POP markers alone can not predict the integrated xenoestrogenic serum activity. Correlations
to the POP markers were found at the extreme edge; the Inuit's and Warsaw study groups eliciting high frequency of samples
with ER antagonistic and agonistic activity, respectively. We suggest that the variation in xenoestrogenic serum activity reflects
differences in POP exposure mixture, genetic factors and/or life style factors.
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1. Introduction
Human exposure to environmental contaminants is ubiq-
uitous and affects also individuals living far away from the
source of contaminants such as industries, combustion
and waste disposal sites. Mainly caused by dietary expo-
sure and due to their resistance to environmental and
biotic degradation persistent organochlorine pollutants
(POPs), e.g. chlorinated pesticides and polychlorinated
biphenyls (PCBs), accumulate in body fat tissues of
humans and animals. Many POPs can mimic hormone
activities and are, therefore, potential endocrine disrupt-
ers (EDs) suspected to increase the risk of cancer, birth
defects, reproductive and neuro-immune disorders [1-3].
To date, no clear-cut evidence for adverse endocrine-
related human health effects of POPs have been obtained
at the individual or population level. However, data from
studies on wild-life species, laboratory animals and
biomarker effects in vitro have strengthened the need for
further research to address the concern.
The sex steroid receptors such as the estrogen receptor α
(ERα) and ERβ and the androgen receptor (AR) belongs to
the nuclear receptor family and are generally ligand-
dependent transcription factors [4-6]. Their genomic
mediated pathway include steps as binding of ligand to
receptor, translocation into nucleus and binding of the
receptor-ligand complex to a specific DNA response ele-
ment causing a gene response. Androgens and estrogens
are not male or female hormones only. Both hormones
are important in both sexes and an absolute necessity for
reproductive development including male fertility [7].
The steroid androgen hormones, testosterone and dihy-
drotestosterone, are necessary for the normal male pheno-
type and the presence of ERα and ERβ in human foetal
testis and epididymis cells indicates that estrogens play a
physiological role in regulations of spermatogenesis in
mammals [8-10].
There is extensive data of in vitro mechanism based mod-
els on endocrine-related POPs effects on sex hormonal
systems [11-14]. Although much less potent compared to
17β-estradiol (E2) the three PCB congeners CB-138, CB-
153 and CB-180, comprising up to 50% of the bio-accu-
mulated sum of PCBs, elicit a receptor mediated antiestro-
gen and/or antiandrogen in vitro activity [15], and
similarly some hydroxylated PCBs exert low potency
estrogenic and/or antiestrogenic effects [16,17]. Generally
PCBs do not bind to the sex hormone binding globulin
(SHBG) or at very low affinity [18], which may cause a
higher bio-availability of the compounds. Animal studies
have indicated that prenatal exposure to POPs as PCBs,
dioxins and p,p'-DDE is associated with reduced male fer-
tility [19-24], whereas the effect of POPs on human fertil-
ity is still controversial [25,26], and therefore an
integrated risk assessment of EDs is needed [27]. In vitro
studies of xenoestrogen mixtures present at or below their
no-observed-effect concentration (NOEC) or sub-NOEC
was demonstrated to cause a dramatic additive enhance-
ment of hormone actions [28,29]. Rather than monitor-
ing the level of identified xenoestrogens, the integrated
biological activity was used to estimate the xenobiotic
burden of serum samples using [17,30-32].
The present study was a part of the EU supported research
project Inuendo [33]. The specific aim of the present study
was to compare xenoestrogenic activities across Inuit's
and European regions, and to evaluate whether the serum
levels of the POP biomarkers, CB-153 and p,p'-DDE, were
associated to the actual xenoestrogenic net activity in
blood.
2. Subjects and methods
2.1 Study population and collection of blood samples
Based on earlier reports of POP body burdens four popu-
lations were included in the Inuendo study [33] for a
cross-sectional fertility study representing a wide range of
POP burdens. For the present study the aim was to recruit
300 male spouses to pregnant women in Greenland, War-
saw (Poland) and Kharkiv (Ukraine), and a subgroup (n
= 100) of an already established cohort of fishermen from
Sweden was also included in the study [25]. A general cri-
terion for eligibility was that the participants had to be
born in the country of study and at least 18 years of age.
Serum samples were randomly selected from the main
Inuendo study groups, and the intension was to analyse
serum samples including high and low POP exposure
within each study group. However, because of the limit in
project timing and in some cases too little blood was col-
lected for the analysis, serum samples were randomly
selected before POP determination, and fewer serum sam-
ples were analyzed. Males were recruited during 2002–
2004 in Greenland (n = 72; Sisimiut, West Coast n = 50,
and Tasiilaq, East Coast n = 22), in Warsaw, Poland (n =
99) and in Kharkiv, Ukraine (n = 88) [25]. Earlier studies
have reported high POP levels in Greenlandic Inuit's and
differences in levels between habitants of the East and
West Coast of Greenland [34,35]. However to keep simi-
lar power in the four study groups the statistical evalua-
tion was carried out on the combined Greenlandic data
only.
Information about demographic and lifestyle factors as
age, body mass index (BMI), intake of seafood, coffee,
smoking habits, and alcohol consumption was collected
by interviews (Table 1) [25,35]. Venous blood samples
were collected into 10 ml vacuum tubes and after centrif-
ugation the serum was transferred to Nunc tubes and
stored at -80°C for later analysis [35]. The study was
approved by the local ethical committees representing allEnvironmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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participating populations and all subjects signed an
informed consent.
2.2 Determination of CB-153 and p,p'-DDE in serum
Serum concentrations of CB-153 and p,p'-DDE were deter-
mined using solid phase extraction (SPE) and on-column
degradation of lipids followed by analysis with gas chro-
matography mass spectrometry as described [35]. CB-153
and p,p'-DDE levels were adjusted for serum lipids. Levels
of detection, coefficients of variation and participation in
quality control programs have been described in detail
elsewhere [35,36].
2.3 SPE-HPLC fractionation of the serum samples
To obtain the serum fraction containing the actual mix-
ture of bio-accumulated POPs a solid phase extraction
(SPE) followed by high-performance liquid chromatogra-
phy (HPLC) fractionation was performed on 3.6 ml
serum [37]. Similar to the described methods [17,30,38]
the POPs were extracted from the serum by SPE separation
on a Spherisorb Si 60 analytical column (250 × 4.6 mm
i.d., 5 µm particle size, Waters, Milford, MA, USA). This is
a normal phase column and thus the separation is based
on lipophilicity. This crude serum extract was then further
processed using HPLC in order to separate the POPs from
the endogenous hormones. The first fraction (F1: 0.00–
5.30 min, protected from light in brown tubes) was set up
to include most POPs while leaving out endogenous hor-
mones by testing 18 lipophilic chemicals including PCBs,
pesticides, akylphenols, bisphenol A, 6 endogenous hor-
mones (estrogens and androgens), and 1 oral contracep-
tive on the HPLC system using retension times as
discriminating factor. This F1 SPE-HPLC fraction was
evaporated to near dryness and frozen for later ER medi-
ated chemical activated luciferase gene expression (ER-
CALUX) analysis. ER-CALUX analyses of the HPLC frac-
tions F1, F2.1 (5.30 – 12.0 min) and F2.2 (12.00 – 14.5
min) verified that the endogenous hormones were sepa-
rated from F1 but found in F2.1 and F2.2. Moreover, com-
parison of SPE-HPLC F1 extracts obtained by our system
with F1 extracts obtained from another laboratory (Insti-
tute of Public Health, University of Southern Denmark)
elicited same responses in the ER-CALUX analyses [37].
Two pools of blood bank serum (Aarhus Sygehus, Den-
mark), one male (KHM) and one female (KHF), were dis-
tributed into tubes with 3.6 ml and stored at -80°C. One
sample from each sex was weekly processed by the SPE-
HPLC method in parallel with the project samples serving
as serum controls for the cleanup procedure. The day to
day inter assay coefficient of variation (CV) of the SPE-
HPLC + ER-CALUX analyses of these control blood sam-
ples were ≤ 13%.
2.3.1 Dissolving the SPE-HPLC samples
The SPE-HPLC extracts samples (project samples and con-
trols) were thawed and protected from light during han-
dling. Sample solvent, 20 µl EtOH:H2O:DMSO
(50:40:10), was added to each sample tube and the sam-
ples were placed in an Eppendorf Thermomixer Comfort
Table 1: Demographic and life style characteristics of men in the study groups
Greenland n = 72 Warsaw n = 98 Sweden n = 100 Kharkiv n = 88 All n = 358
Age median 30 (70) 30 (97) 47 (96) 25 (85) 31 (348)
years min-max 18–46 24–46 24–68 16–45 16–68
BMI median 26 (72) 25 (96) 26 (99) 24 (86) 25 (353)
Kg/m2 min-max 12–38 19–38 22–37 19–36 12–38
Alcohol median 2.0 (36) 3.5 (86) n.a 2.5 (66) 3.0 (188)
drink/week min-max 0–21 0–30 0.2–15 0–30
Smoking ever % 89 (71) 50 (97) 60 (98) 82 (87) 68 (353)
Seafood median 1.5 (68) 1.0 (89) n.a 4.0 (86) 2.0 (243)
days/week min-max 0–9.0 0–9.0 1.0–9.0 0–9.0
Coffee median 3.0 (62) 2.0 (83) n.a 2.0 (37) 2.0 (182)
cups/day min-max 0–20 0–6.0 0.5–7.0 0–20
Total testosterone median 15 (36) 13 (76) 12 (99) 18 (88) 14 (299)
nmol/l m i n - m a x 3 . 2 – 2 56 . 5 – 2 34 . 2 – 2 88 . 4 – 3 23 . 2 – 3 2
Estradiol median 59 (35) 71 (76) 67 (99) 78 (88) 70 (298)
nmol/l min-max 31–89 45–297 25–154 33–144 25–297
The values in the bracket are the numbers of individuals with data for the specific demographic and life style characteristics.Environmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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at 550 rpm and 37°C for 15 minutes. Then 200 µl growth
media [0.5% Dextran-Charcoal treated foetal calf serum
(DC-FCS, Hyclone, Bie & Berntsen, Aarhus, DK) in phenol
red-free Dulbecco's Modified Eagle's Medium (DMEM)
(Gibco, Invitrogen, Taastrup, DK) supplemented with 4
mM glutamine (Sigma-Aldrich, Vallensbaek Strand, DK)
and 1.28 mg/ml garamycin (Schering-Plough, Dassel,
Germany)] was added to each sample and the shaking at
550 rpm and 37°C was continued for another 15 min-
utes. Then each sample was transferred to two new test
tubes (100 µl/tube) each containing 400 µl growth media
with or without the normal ER ligand E2, respectively, and
used for ER-CALUX determinations.
2.4 ER-CALUX assay
The stable transfected MVLN human breast cancer cell line
(kindly provided by M. Pons, France) carrying the endog-
enous ERα and ERβ genes, and the introduced estrogen-
response-element (ERE)-luciferase reporter vector [39]
was used for determination of ER-CALUX activities as
described [40]. The measured luciferase data was cor-
rected to cell protein (internal control), and expressed in
relative light units per microgram protein (RLUs/µg pro-
tein). All controls and SPE-HPLC F1 serum extracts (100
µl/well) were analysed in triplicate. If one of the triplicate
values deviated more than 30% the mean was calculated
from two wells only. An E2 dose-response control in the
concentration range from 0.05 pM to 500 pM (solvent
96% ethanol = 0.1%) was performed in parallel each anal-
ysis day as described [14,40]. The maximal effective con-
centration (EC100), the half maximum effective
concentration (EC50), and EC40 of E2 was calculated to
150 pM, 33 pM and 25 pM, respectively, by fitting the
dose-response data into Chapman, 4 parameter sigmoid
equation curve using Sigma Plot 8.0 (SPSS, Chicago, IL,
USA). The E2-EC100 and the E2-EC40 were used as parallel
positive controls on each plate in each assay. Xenoestro-
genic activity (XER) was determined by exposure of the
cells to serum extracts alone and XERcomp activity upon
co-exposure of the cells to serum extract + 25 pM E2
(EC40). The solvent controls of XER and XERcomp activity
were sample solvent only and the sample solvent plus 25
pM E2 (EC40), respectively (see 2.3.1 for handling proce-
dure), and for XER and XERcomp activity calculation the
respective solvent controls (RLU/µg protein) were set to 1.
Finally, the data was given as activity per ml serum and the
values of the solvent controls were 3.13 RLU/ml serum.
The E2 equivalence (XER-EEQ) value of the agonistic XER
activities was obtained by interpolation of data onto the
Chapman 4 parameter sigmoid curve using the dose-
response E2 Sigma Plot curve. Both the average ER-
CALUX inter-CV of the solvent controls and intra-individ-
ual CV for serum sample extracts were below 5%.
No cell toxicity on MVLN determined by CellTiter 96 Cell
Proliferation assay from Promega (Madison WI, US) [40]
was observed after exposure to SPE-HPLC extracts.
2.5 Statistical analysis
The comparisons of means between XER, XERcomp and
XER-EEQ were performed by the Oneway-ANOVA test.
When ANOVA indicated significant group difference com-
plementary multiple comparison ad hoc tests were used.
The test for homogeneity of variance was performed with
Levene's test. The least significant difference (LSD) pair
wise multiple comparison test was used for the variables
with equal variance (p ≥ 0.05) and Dunnett's T3 test was
used for the variables with an unequal variance (p ≤ 0.05).
The association in each study group between POP marker
and xenoestrogen activity was evaluated by means of
Spearman's rank correlation. The overall association
between the POP marker and xenoestrogen activity across
the study groups (combined data) were evaluated by com-
paring the regression lines for each study group (multiple
regression analysis).
Our hypothesis is that a potential determinant of POP
bioaccumulation might also be a potential determinant
for serum xenoestrogenic activity. As known from the lit-
eratures and also from an assessment of the total Inuendo
study populations [25,35] age and seafood are such deter-
minants. Moreover, lifestyle characteristics (Table 1) were
evaluated as potential determinants of XER and XERcomp
levels of combined data and the separate study groups.
Using multivariate linear regression analyses, assessing
the impact of the POP biomarkers on XER and XERcomp,
the impact of potential confounders were evaluated by
entering blocks of variables together with either CB-153
or p,p'-DDE as follows: In the first step age and seafood
intake (continuous variables) were included in the model,
and in the second step additionally smoking status
(smoked ever yes/no), BMI, and coffee intake was
included as continuous variables. Alcohol consumption
was only recorded for limited number (n = 188, see Table
1) of subject and not for the Swedish study group. There-
fore, the second step was carried out with and without
alcohol consumption in the potential confounder model,
which did not change the overall pattern of non-adjusted
to adjusted data. Due to many missing values on the
potential confounders (Table 1) the number of available
observations in the confounder analyses are much smaller
than in the unadjusted analysis on the full dataset (full
dataset (XER, XERcomp and POP markers) N = 348; first
step of confounders: N = 231; second step: N = 172). A
reduction of the number of observations with 50% might
introduce serious selection problems, and hence the con-
founder analyses might lack greater validity.Environmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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The XER and XERcomp activities were determined in pro-
tein free serum extracts free of endogenous estrogens and
testosterone. As a method verification Spearman's rank
correlation analyses of XER and XERcomp against deter-
mined blood levels of estradiol and testosterone (total
and free) [41] were performed on the combined study
group data.
Normal distribution was assessed by Q-Q plots. To
improve normality and homogeneity of variance, the XER
and XERcomp activities as well as lipid adjusted CB-153
(lip-CB-153) and p,p'-DDE (lipDDE) were natural loga-
rithmic transformed and the statistical analyses were per-
formed on the ln-transformed data. The POP variables
were treated as continuous variables. The statistical analy-
sis was performed in SPSS 10.0 (SPSS Inc, Chicago, IL)
with the significance level p ≤ 0.05.
3. Results
3.1 Basic characteristics, CB-153, p,p'-DDE and 
xenoestrogenic serum levels
The distribution of demographic and lifestyle factors
(Table 1) and serum CB-153 and p,p'-DDE median levels
(Table 2) that may potentially influence the ER-mediated
activities of the 358 adult males in this study were similar
with that obtained for the total Inuendo study population
[25,35]. Correlation between serum concentration of CB-
153 and p,p'-DDE was found with higher correlations in
Greenland (rs = 0.94) and Sweden (rs = 0.75), while rela-
tively lower correlation was observed for the study group
of Kharkiv (rs = 0.45) and Warsaw (rs = 0.28).
Table 2: Xenoestrogenic serum activities, estradiol equivalents and lipid adjusted CB-153 and p,p'-DDE in serum of the study groups
Greenland Warsaw Sweden Kharkiv ALL*4 All study group 
data*5
XER*1RLU/ml serum N 72 98 100 88 358 0.003
Median 2.89 3.09 3.04 3.15 3.05
Mean 2.92 3.30 3.22 3.17 3.17
Min 1.0 2.4 2.4 1.0 1.1
M a x 6 . 06 . 51 28 . 01 2
% agonist 1 21 12 14 -
% antagonist 35 5 12 17 -
XER-EEQ pg/g lipid*2 N1 ♣ 21 10 11 43 0.63
Median - 103 76♥ 139 114
Mean - 166 161 179 171
Min - 44 50 80 44 
Max - 516 364 580 580
XER comp*3RLU/ml serum N 7 29 49 48 8 3 4 8<  0 . 0 0 1
Median 2.65 2.96 2.90 2.88 2.86
Mean 2.69 3.29 2.89 2.87 2.95
Min 2.0 1.8 1.0 1.1 1.0
Max 3.8 7.0 6.8 4.5 7.0
% add/syn 1 13 3 1 -
% antagonist 71 7 19 30 -
CB-153 ng/g lipid N 74 100 98 82 354 < 0.001
Median 220 16 210 47 79
Min 5.1 33 4.1 5.5 3.3
Max 5500 130 1500 200 5500
DDE ng/g lipid N 74 100 98 82 354 < 0.001
Median 630 570 240 880 560
Min 66 240 55 324 55
Max 13000 2100 2300 12000 13000
In the independent assays significant differences between the triple serum extract determinations and their respective solvent controls (% agonists/
additive/synergistic) and % antagonists, were tested by the Student's t-test (Microsoft Office Excel, significance level p = 0.05). *1: XER: 
Xenoestrogenic agonistic or antagonistic activity of serum extract alone: the solvent control = 3.13 RLU/ml serum. % agonistic and % antagonistic 
indicates the % of samples eliciting a significantly increase or decrease in XER activity compared to solvent control, which was set to 1. *2: XER-
estradiol equivalence (XER-EEQ) of the samples eliciting significantly agonistic activity; data calculated by interpolation to the E2 dose response 
curve using the sigma plot program. ♥ : One Swedish sample was too high to calculate the XER-EEQ. ♣ : One serum sample from Greenland only 
had an agonistic action, thus no XER-EEQ value is given. *3: XERcomp; XER competitive activity of serum extract + 25 pM 17β-estradiol (E2-EC40); 
% add/syn: additive/synergistic and % antagonistic indicates the % of samples responding with a further increase or a decrease of the E2-EC40 
induced activity, respectively, compared to the E2-EC40 solvent control = 3.13 RLU/ml serum, which was set to 1;. *4: XER activity includes 358 
samples, however, only 348 of theses samples were applied to the XERcomp analyses. All of the samples had CB-153 and p,p'-DDE determined. *5: 
One-way ANOVA (p value) evaluation of the combined study group data except for XER-EEQ including only the European groups. In transformed 
data was used.Environmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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The Greenlandic serum extracts elicited predominantly
antagonistic effect on XER (35%) and XERcomp (71%),
whereas the European samples elicited relatively higher
frequency of XER agonistic activity (12–21%) of which
the Warsaw samples had the highest mean of XER/XER-
comp (Table 2 and Figure 1).
Oneway ANOVA analyses showed significant differences
between the study groups (Table 2). Multiple compari-
sons of means showed that Inuit XER activities signifi-
cantly differed from each of the three European study
groups (p ≤ 0.03); whereas the XER activity and XER-EEQ
of the European study groups did not mutually differ.
Only one sample from Greenland elicited XER agonistic
activity and thus no XER-EEQ data was given for the
Inuit's. The XERcomp activity of the Warsaw group dif-
fered from all other study groups (p ≤ 0.004).
3.2 Associations between xenoestrogenic activity and CB-
153 and p,p'-DDE
XER activity for Inuit's showed an inverse correlation to
the p,p'-DDE levels (rs = -0.29; p = 0.02) and borderline
inverse to CB-153 (rs = -0.22; p = 0.07). For the Warsaw
study group the XER activity showed a significant positive
correlation to the p,p'-DDE data (rs = 0.21; p = 0.04), and
for XER-EEQ a significant negative correlation to CB-153
(rs = -0.45; p = 0.04) was found (See Additional file 1:
Spearman's correlation analyses between xenoestrogenic
serum activities and the level of CB-153 and p,p'-DDE).
No further correlations between XER, XERcomp or XER-
EEQ and any of the two POP markers were found. Adjust-
ment for the potential confounders in the multivariate
regression model did not give any different results for the
impact of the POP biomarkers on XER and XERcomp as
compared with the unadjusted models, neither for the
combined data or each study group (data not shown).
3.3 Multiple regression of xenoestrogenic activity on POP 
data across the study groups
Scatter plots of XER or XERcomp against CB-153 or p,p'-
DDE for the four study groups are shown in Figure 2. Mul-
tiple regression analysis of both response variables (XER
and XERcomp) showed homogeneity of slopes between
study groups and CB-153/p,p'-DDE (Table 3), i.e. parallel
regression lines among study groups. Furthermore, a
model with parallel regression lines showed significant
differences between the intercepts of the study groups
(Table 3). Thus the differences in XER/XERcomp between
study groups found by Oneway ANOVA (Table 2) and
multiple comparisons still exist after adjustment for CB-
153 or p,p'-DDE. Finally, we note that although correla-
tions was observed between XERs and the POP markers
for the Greenlandic and Warsaw study groups (Supple-
ment), for the combined data the associations between
XER/XERcomp and CB-153/DDE, as measured by the
common slopes, are very weak and not statistically signif-
icant (Table 3).
3.4 Correlations between xenohormone activities and 
endogenous hormone levels
To verify the exclusion of endogenous hormones from the
SPE-HPLC- F1 serum extracts used for CALUX activity
measurements, the XER, XER-EEQ and XERcomp results
were evaluated for possible correlation to blood estradiol
(pmol/L) and testosterone (nmol/L) (free and total) lev-
els. No correlations were found between the serum XER/
XERcomp activities and blood sex hormone levels neither
for the combined data nor for the separate study groups.
4. Discussion
In the present study we determined the actual xenoestro-
genic net activity in serum of adult men from Greenland,
Sweden, Warsaw (Poland) and Kharkiv (Ukraine), repre-
senting populations with different POP exposure patterns
(Table 2) [34,35,42,43]. For the combined data no strong
consistent correlations between serum xenoestrogenic
activity and the two POP proxy markers, CB-153 and p,p'-
DDE, was observed. Significant correlations between
marker POPs and xenoestrogenic serum activity was
found for Inuit's and the Warsaw group, having the lowest
and highest ratio of agonist:antagonist samples, respec-
tively; an inverse association of XER activity to the p,p'-
DDE and CB-153 levels for Inuit's, and for the Warsaw
group a positive and a negative association of XER to p,p'-
DDE and XER-EEQ to CB-153, respectively. Because of the
high inter-correlation between CB-153 and p,p'-DDE for
the Inuit's it can not be assessed which of the two POPs
exert the main impact. However, for the Warsaw group the
very low concentration of CB-153 and low inter-correla-
tion of marker POPs indicates that p,p'-DDE might have a
positive effect on XER activity, and CB-153 an inverse
impact on agonistic XER as elicited by XER-EEQ. Overall,
these data might be explained by the high level of PCBs in
Greenland with predominant anti-estrogenic actions
[15,17,44-46] and relatively high level of p,p'-DDE in the
Warsaw group having weak estrogenic action
[17,28,47,48]. However, that does not explain why no
correlations were observed for the Swedish and Kharkiv
groups since they had a CB-153 and p,p'-DDE marker pro-
file similar to Greenland and Warsaw, respectively. Multi-
ple regression analyses showed, that the determined
differences of XER and XERcomp activity between the
study groups could not be explained by the two selected
POP proxy markers alone neither in combination with the
measured potential confounders in the present study.
However, the combined XER vs. CB-153 data showed
homogeneity across the study groups, had common
slopes and similar intercept (p = 0.05, Table 3, Figure 2),
and assuming a common intercept a significant (β = -
0.132, p = 0.01) negative correlation between CB-153 andEnvironmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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The xenoestrogenic CALUX activity of study groups Figure 1
The xenoestrogenic CALUX activity of study groups. (A) Agonistic activity of serum extracts alone (XER) and (B) com-
petitive XER activity upon coexposure with 25 pM E2 (EC40) (median, quartiles (25% and 75%) and extreme variables). For the 
Swedish study group an extreme agonistic (A) RLU value of 12.02 was determined (not shown). The reference line of the 
respective solvent controls ± SD (3.13 ± 0.16) are given as dotted lines.
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XER activity was found. Future studies might elucidate
whether our observations are serendipitous.
Between the groups the XER and XERcomp activities dif-
fered significantly. The Inuit's clearly differed from the
European study groups eliciting no agonistic but high fre-
quency of samples (71%) with antagonistic action. In
contrast, the European serum samples exerted both ago-
nistic (12 – 21% of the samples) and antagonistic effects
(7 – 30% of the samples).
The heterogeneous pattern of xenoestrogenic correlations
to CB-153/p,p'-DDE levels and also the differences in
xenoestrogenic activity among the study groups might be
explained by different exposure profiles e.g. : i) the estro-
genic effects elicited by ER transactivity is a consequence
of the combined net effects of many POPs having either
ER agonistic or ER antagonistic actions; ii) the two
selected POP markers do not reflect and/or represent the
chemicals primarily responsible for the determined
xenoestrogenic effects; iii) the combined response of the
serum mixture is significant affected although the concen-
tration of the single compounds found in human serum is
lower than that needed to elicit a response of the com-
pound on its own in an in vitro system; and finally iv) the
net XER/XERcomp activities is the net response of expo-
sure patterns, genetic background and life style factors. In
summary, based on the two selected POP markers only, it
is hard to predict the net xenoestrogenic impact in vivo as
well as in the present ex vivo xenoestrogenic measure-
ments.
The use of CB-153 and p,p'-DDE in serum as index
biomarkers of POP exposure has been supported by sev-
eral previous studies [49-52]. However, it must be taken
into consideration that the relative concentrations of non-
coplanar and co-planar PCBs can differ between regions
depending on varying exposure sources. The ratio
between serum levels of CB-153 (and other non-coplanar
congeners) and co-planar PCBs was higher in Canadian
Inuit's than in Canadian Caucasians from the Arctic area
[53], which calls for caution using CB-153 as a global
exposure marker for POP as well as for xenoestrogenic
serum activities. In the present study it might be expected
that the ratio between non-dioxin-like, non-coplanar
PCBs (e.g. CB-153) and co-planar PCB (e.g. CB-126) also
is higher for the Greenlandic Inuit's compared to the three
European study groups.
In vitro studies demonstrated that the combined effect of
several xenoestrogens including POPs at sub-NOEC
exerted an additive effect, which led to dramatic change in
estrogenic in vitro activity [28,29]. To elucidate potential
human and wildlife responses to the combined impact of
accumulated xenoestrogens it remains to be demon-
strated mechanistically how chemicals with antiestrogen
effects can modify the response of chemicals acting estro-
genic in a concerted action. It can be argued that xenoes-
trogenic equivalents contribute only a few percent to the
endogenous hormone activity – even when possible
higher bioavailability of the xenobiotics is taken into con-
sideration. However, considering the further increase of
XERcomp above the reference control (25 pM E2) we cal-
culated (using Sigma Plot and the data of the E2 dose-
response curve) for this subgroup of men (n = 86) a fur-
ther mean activity increase of 47% and 21% in relation to
the minimum (34 pM) and mean (70 pM) endogenous
estradiol level, respectively. Since the level of endogenous
estrogens is much lower in male than in female the
xenoestrogenic activity might have higher impact on
health risk in males.
In studies using similar approach as the present no corre-
lation between neither CB-153 nor p,p'-DDE and xenoes-
trogenicity were found. In contrast to our determination
of the more specific impact of serum xenoestrogens on ER
transactivation, the other studies used the E-screen MCF-7
cell proliferation as end point [17,30-32]. Moreover, we
analyzed the xenoestrogenic action in male blood sam-
ples whereas the other four studies were focused on
female adipose tissues [30-32] and female serum from
pregnant and non-pregnant women [17]. These studies
determined a higher frequency (~ 60–70%) of subjects
with significantly increased estrogenic activity in the non-
polar serum fraction of Spanish and Faroese women. For
non-pregnant Danish women the frequency of subjects
Table 3: Multiple regressions of the combined study group data
Response variable Exposure 
variable
Homogeneity of 
slopes (p-value)
Common slope 
Estimate (SE) p-value
Common intercept 
(p-value)
Adjusted R- square
XER (N = 348) CB-153 0.86 -0.01 (0.01), 0.34 0.05 0.029
p,p'- DDE 0.24 -0.03 (0.02), 0.12 0.005 0.034
XERcomp (N = 338) CB-153 0.20 0.01 (0.02), 0.45 <0.001 0.087
p,p'- DDE 0.15 -0.006 (0.02), 0.71 <0.001 0.086
Response and exposure variables are ln-transformed in the analysis. Homogeneity of slopes: p-value for the test for homogeneity of slopes between 
study group and exposure variable. Common slope: the estimated common slope across study groups assuming no interaction. Common intercept: 
p-value for the test of a common intercept across study groups assuming a common slope. Adjusted R-square assuming a common slope.Environmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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exceeding the background level was 22.7%, similarly to
the frequency determined for the European males in the
present study. In support to our data it was recently
reported that high levels of PCBs in Slovakia male serum
samples were associated with a decreased ER mediated
activity and increased AhR mediated activity [46].
Schematic illustration of xenoestrogenic activities related to the POP markers Figure 2
Schematic illustration of xenoestrogenic activities related to the POP markers. Xenoestrogenic (XER) and com-
petitive XER (XERcomp) serum activities related to CB-153 and p,p'-DDE levels for the four country based study groups as a 
relation between (A) XER and p,p'-DDE, (B) XER and CB-153, (C) XERcomp and p,p'-DDE, and (d) XERcomp and CB-153. 
The values are given as ln transformed data. 
                                                                                                                                      
Greenland:                 ; Warsaw:               ; Sweden:                 ; Kharkiv: * Environmental Health: A Global Access Science Source 2006, 5:12 http://www.ehjournal.net/content/5/1/12
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Recently, estrogenicity of adipose tissue extracts including
bio-accumulated xenoestrogens was shown associated
with higher risk of breast cancer in leaner women [32].
4.1 Conclusions and perspectives
Across the four study groups no strong consistent correla-
tion between xenoestrogenicity and the two POP proxy
markers was found. Thus, the CB-153 and p,p'-DDE alone
are not optimal global POP markers of the integrated
xenoestrogenic serum activity. However, between the
study groups a clear difference in serum xenoestrogenicity
as well as differences in correlation to the CB-153 and p,p'-
DDE proxy markers was found. Correlations to the POP
markers were found for the two study groups at the
extreme edge: Inuit's with high sample frequency of anti-
estrogenicity, and the Warsaw group with higher fre-
quency of samples with estrogenicity. In support to POP
biomarker determinations, the present ex vivo biomarker
xeno-activity assay may be useful in assessment of geo-
graphical surveys for the impact of environmental xenoes-
trogens, reflecting differences in POP exposure patterns.
On the other hand, exposure assessment based upon
measurements of the actual xenoestrogenic serum activity
of the isolated SPE-HPLC, F1- POP- fraction may fail to
detect effects accomplished 1) by other non-lipophilic
compounds in serum, 2) through other receptors or 3) by
other mechanisms. More work still needs to be done to
fully understand to which extent ex vivo measurements of
receptor-transactivation reflect the in vivo situation.
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